ARCUTIS BIOTHERAPEUTICS
Arcutis Biotherapeutics is a privately held clinical-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. The company was founded in 2016 and is based in Westlake Village, California.
ARCUTIS BIOTHERAPEUTICS
Industry:
Biopharma Biotechnology Health Diagnostics Pharmaceutical Therapeutics
Founded:
2016-01-06
Address:
Westlake Village, California, United States
Country:
United States
Website Url:
http://www.arcutis.com
Total Employee:
251+
Status:
Active
Contact:
805-418-5006
Total Funding:
833.5 M USD
Technology used in webpage:
Domain Not Resolving CrUX Top 50m ReCAPTCHA V2 JQuery CDN Microsoft COVID-19 Microsoft Azure Mobile Optimized AddThis Akamai Hosted
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
AZTherapies
AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Checkmate Pharmaceuticals
Checkmate Pharma is a clinical stage biopharmaceutical company developing a new approach for cancer immunotherapy.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Eidos Therapeutics
Eidos Therapeutics is a clinical-stage biotech company developing novel, genetically targeted therapies to improve the lives of patients.
Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company committed to developing therapy for the treatment of hypertension.
Sparrow Pharmaceuticals
Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for disorders of corticosteroid excess.
Stealth BioTherapeutics
Stealth BioTherapeutics is a clinical-stage biotechnology company focused on genetic diseases.
Current Advisors List
Board_member
2020-04-01
Board_member
Current Employees Featured
John Smither Chief Financial Officer @ Arcutis Biotherapeutics
Chief Financial Officer
2019-05-01
Matthew Moore Chief Business Officer @ Arcutis Biotherapeutics
Chief Business Officer
2021-01-01
David Osborne Chief Technical Officer and co-founders @ Arcutis Biotherapeutics
Chief Technical Officer and co-founders
Todd Edwards Chief Commercial Officer @ Arcutis Biotherapeutics
Chief Commercial Officer
2023-09-01
Patricia Turney SVP, Operations @ Arcutis Biotherapeutics
SVP, Operations
2019-12-01
Patrick Burnett Chief Medical Officer @ Arcutis Biotherapeutics
Chief Medical Officer
Kenneth Lock Chief Commercial Officer @ Arcutis Biotherapeutics
Chief Commercial Officer
Nakul Vyas Head of Data, Analytics, and Digital Innovation @ Arcutis Biotherapeutics
Head of Data, Analytics, and Digital Innovation
Frank Watanabe President and CEO @ Arcutis Biotherapeutics
President and CEO
Howard Welgus Chief Medical Officer @ Arcutis Biotherapeutics
Chief Medical Officer
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2022-09-08 | Ducentis BioTherapeutics | Ducentis BioTherapeutics acquired by Arcutis Biotherapeutics | 400 M USD |
Investors List
SLR Capital Partners
SLR Capital Partners investment in Post-IPO Debt - Arcutis Biotherapeutics
Frazier Healthcare Partners
Frazier Healthcare Partners investment in Series C - Arcutis Biotherapeutics
HBM Healthcare Investments
HBM Healthcare Investments investment in Series C - Arcutis Biotherapeutics
RA Capital Management
RA Capital Management investment in Series C - Arcutis Biotherapeutics
BlackRock
BlackRock investment in Series C - Arcutis Biotherapeutics
Pivotal bioVenture Partners
Pivotal bioVenture Partners investment in Series C - Arcutis Biotherapeutics
Goldman Sachs
Goldman Sachs investment in Series C - Arcutis Biotherapeutics
Omega Funds
Omega Funds investment in Series C - Arcutis Biotherapeutics
OrbiMed
OrbiMed investment in Series C - Arcutis Biotherapeutics
Bain Capital
Bain Capital investment in Series C - Arcutis Biotherapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2023-09-27 | Arcutis Appoints L. Todd Edwards as Chief Commercial Officer |
Official Site Inspections
http://www.arcutis.com Semrush global rank: 2.42 M Semrush visits lastest month: 7.85 K
- Host name: 23.185.0.3
- IP address: 23.185.0.3
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Arcutis Biotherapeutics"
Arcutis Fact Sheet - Arcutis Biotherapeutics
Arcutis Biotherapeutics, Inc. 3027 Townsgate Road, Suite 300 Westlake Village, CA 91361 Corporate contact : information@arcutis.com 805-418-5006 Media and investor contact : …See details»
Arcutis Announces Acquisition of Ducentis BioTherapeutics Ltd.
“This acquisition is an important step in realizing our vision of becoming the leading, innovation-driven medical dermatology company, and leverages our deep dermatology expertise and …See details»
Medical dermatology innovation | Arcutis Biotherapeutics
At Arcutis, meaningful innovation means focusing on unmet needs in the treatment of immune-mediated skin diseases. With extensive medical dermatology development expertise and a unique dermatology drug …See details»
Arcutis Biotherapeutics - Crunchbase Company Profile …
Organization. Arcutis Biotherapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... Arcutis Biotherapeutics reported significant revenue growth in Q4 2023 and …See details»
Our Approach to Clinical Trials - About Us - Arcutis …
Arcutis strives to enrol a diverse population in our clinical trials in order to more accurately characterize how new treatments perform in different groups. ... Our commitment to Diversity & Inclusion spans all levels of our organization …See details»
Committee Composition - Arcutis Biotherapeutics
The Arcutis Board of Directors is a seasoned group with broad leadership backgrounds. Their current and previous roles as biotech executives, physicians, researchers and investors …See details»
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) | LinkedIn
Arcutis (Nasdaq: ARQT) was founded in 2016 to address significant unmet needs in medical dermatology. The company is an early commercial stage biopharmaceutical company focused …See details»
Arcutis - Canada - Fact Sheet - English - Arcutis Biotherapeutics
Arcutis Biotherapeutics, Inc. 3027 Townsgate Road, Suite 300 Westlake Village, CA 91361 For more information, visit arcutis.ca Corporate contact : canada@arcutis.com 1-833-427-2884 …See details»
About Us - Arcutis Biotherapeutics
A career at Arcutis is an opportunity for growth at an exciting and innovative biotherapeutics company committed to making a difference in the lives of patients and their families. At …See details»
Member Spotlight: Arcutis Biotherapeutics - Biocom California
May 16, 2024 Arcutis Biotherapeutics may not be a household name yet, but the LA-based dermatology company has been revolutionizing the treatment of chronic skin conditions since …See details»
Meaningful Innovation - Arcutis Biotherapeutics
Arcutis applies meaningful innovation as we strive to simplify the management of skin disease for patients and providers alike. Focus areas. Our focus in specific dermatological areas allows us …See details»
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq …
Apr 5, 2024 These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a …See details»
Arcutis Appoints Mas Matsuda as General Counsel and Corporate …
Dec 16, 2021 WESTLAKE VILLAGE, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on …See details»
Arcutis Announces Promotions on Executive Management Team
I have full confidence in their ability to drive our organization forward and position us for even greater achievements in the future,” said Frank Watanabe, president and CEO. About Arcutis …See details»
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq …
3 days ago WESTLAKE VILLAGE, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company …See details»
Arcutis Biotherapeutics - Fortune
Arcutis Biotherapeutics is an empowered team looking at the inclusiveness and engagement across the company—it's a real differentiator and allows anyone in the company to get …See details»
ESG Report - arcutis.ca
About Arcutis Arcutis ESG Program Our Approach to Patient Care Access and Affordability Community Engagement Human Capital Management Developing Top Talent Drug Safety …See details»
Arcutis Biotherapeutics price target raised to $20 from $19 at
2 days ago Mizuho raised the firm’s price target on Arcutis Biotherapeutics (ARQT) to $20 from $19 and keeps an Outperform rating on the shares. The firm says Arcutis is a top pick for 2025 …See details»
Arcutis Cares Patient Assistance - Arcutis Biotherapeutics
Arcutis Cares Patient Assistance Program 9 Commerce Drive Schaumburg, IL 60173. Option 3. Apply over the phone: Call Arcutis Cares and work with a member of our Arcutis Cares patient …See details»
Here's Why Arcutis Stock More Than Doubled in Market Value in …
Jan 3, 2025 In the first nine months of 2024, Arcutis recorded product revenues of $97 million, up more than 500% from the year-ago quarter figure. This has also likely contributed to the …See details»